About Dr Garry Lynch

Garry’s primary speciality is in the structures and functions of proteins and in proteomics. From his PhD at Monash University, he was awarded post-doctoral Research Fellowship and Research Associate awards from Harvard University Medical School, for a wide range of studies, from blood coagulation, wound healing, immunotoxin, monoclonal antibodies to cancer (mesothelioma) projects. Those studies were undertaken with Dr Jan McDonagh (FXIII expert), Dr Henry Slayter (EM expert and co-discoverer of thrombospondin) and Dr Vic Raso (a father of catalytic antibodies), at the Beth Israel Hospital, Dana-Farber Cancer Institute and the Boston Biomedical Research Institute, Boston. Recruited back to Australia, he set-up and led a HIV-Protein Interactions Laboratory at Westmead Hospital and Research Institutes, and held Conjoint Snr Lecturer/Snr Research Fellow appointments at Sydney University

Garry’s research focus through the 1990’s was on HIV cell-entry and this led to notable discoveries of new isoform and dimer structures, cell expressions and interactions for the primary HIV- primary receptor, CD4, and its coreceptor, CXCR4. In the 2000’s at the Aust. Red Cross Blood Service, he performed proteomic research of blood products, and provided scientific advice for an Australian Government Blood Product Review. Pivotal new research studies were performed with A/Prof John Sullivan for the study of IVIG antibodies to pathogenic Influenza (e.g., avian H5N1). Beginning in 2004, this led to his most significant discovery so far, that of an unrealised 2nd pathway of adaptive immunity. Uncovered was found to be a mild type of immunity, termed Collateral Immunity©, which they proposed is capable of delivering broad Seasoned Immune Responses© for viruses and bacteria. As such it can act discretely across different Influenza strains, whilst working co-operatively in the background and shadows of the traditionally known immune-dominant, strain-specific, seasonal-type of immunity. Whilst substantial awareness and acceptance in the scientific community of this complementary pathway of ‘Dark Adaptive Immunity’© has yet to be fully realised; from their published evidence, independent validation and lack of negating evidence, support mounts for its existence. Garry’s research publications and first 2 reviews* on the topic provide grounding evidence for the underlying molecular mechanisms involved and his ongoing research is reinforcing it across different infectious disease scenarios. © GW Lynch, JS Sullivan.

Research (broad): Garry has extensive research expertise in proteomics, virology, microbiology, immunology, thrombosis and haemostasis, blood, cell-biology and the extracellular matrix.
BioArt: In 2014 Garry gained a Diploma of Interactive Digital Design (Concept Art), from the Enmore Design Centre, Sydney Institute. And in parallel with his biomedical research studies, he has been exploring and pursuing the use and application of 2D/3D BioArt and animations to image and reveal the biological stories he studies, and in student BioArt supervision.
Academia & Supervision: He has considerable experience in Supervising Student Research projects for relevant studies and quality theses, and included supervision and mentoring of many highly successful students (>50 across all levels). Several of his students have won university medals, prizes, awards and praise from local and international examiners. His Academic and support roles have included undergraduate lecturing and he has experienced many highly successful local and international collaborations. He is a reviewer of Grants and Fellowships, Journal Articles and examiner of PhD/Masters and Honours theses.

<html />

Selected publications

Ebola GP-
Lynch G.W., et al. Imaging of High and Low Resolution Ebola Envelope GP Structures Composited with in silico Models of Difficult-to-Resolve Sections. J. Mol & Genet Med 9 (4): 186-92, 2015.
Influenza - IVIG - Dark Immunity -
Lynch GW*, et al. Seasoned Adaptive Antibody Immunity for Highly Pathogenic Pandemic Influenza in Humans: Naturally acquired heterosubtypic humoral immunity can guide universal vaccines for novel influenzas. Immunol Cell Biol. 90: 149-158. 2012.
John S Sullivan, et al Garry W. Lynch. Heterosubtypic anti-Avian H5N1 Influenza Antibodies in IVIGs from Globally Separate Populations Protect against H5N1 Infection in Cell Culture. J Mol Genet Med 3 (2): 217-224. 2009.
Lynch GW*, et al, Acquired Antibody Immunity for Avian H5N1 Influenza. J Mol Genet Med. 3 (2): 205-209. 2009.
Stelzer-Braid S, Wong B, Robertson P, Lynch GW, et al. Cross-reactive Influenza A H3N2 and H1N1 antibodies may give false positive results when using serological tests to determine human H5N1 infection. J Clin Virol 43(2): 241-243. 2008.Lynch GW et al. Cross-Reactive anti-Avian H5N1 Influenza Neutralizing Antibodies in a normal ‘Exposure-Naïve' Australian Blood Donor Population. Open Immunol J. 1: 13-19. 2008.
HIV - CD4 - CXCR4 -
Lynch, G.W., et al. Marked differences in the structures and protein associations of lymphocyte and monocyte CD4: Resolution of a novel CD4 isoform. Immunol Cell Biol 84: 154-165, 2006.
Sloane, A.J., et al Lynch, G.W. Marked Structural and Functional Heterogeneity in CXCR4: Separation of HIV-1 and SDF-1 Responses. Immunol Cell Biol 83: 129-143, 2005.
Lynch GW, et al. CD4 is expressed by epidermal Langerhans' cells predominantly as covalent dimers. Exp Dermatol. 12: 700-711, 2003.
Lynch GW, et al. Direct evidence for native CD4 oligomers in lymphoid and monocytoid cells. Europ. J. Immunol. 29: 2590-2602. 1999Web Post: Visualizing Biological Data VIZBI 2018 : ‘Dark Immunity'©
Garry W Lynch and John Sullivan. ‘Dark Immunity'© - Visualizing Biological Data, VIZBI, Museum of Contemporary Art (MCA), Circular Quay, Sydney 1st, June, 2018.Web Post: Visualizing Biological Data VIZBI 2017
Garry W Lynch et al. 8th International Conference of Visualizing Biological Data (VIZBI). Charles Perkins Centre, University of Sydney, Sydney 14-16, June, 2017